Get the Stockscreener App
0.7784
5.42%
-0.0446
After Hours:
.82
0.0416
+5.34%
Humacyte Inc stock is traded at $0.7784, with a volume of 6.89M.
It is down -5.42% in the last 24 hours and down -36.72% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$0.823
Open:
$0.83
24h Volume:
6.89M
Relative Volume:
1.06
Market Cap:
$169.69M
Revenue:
$1.57M
Net Income/Loss:
$-39.34M
P/E Ratio:
-3.2596
EPS:
-0.2388
Net Cash Flow:
$-106.40M
1W Performance:
-8.86%
1M Performance:
-36.72%
6M Performance:
-55.01%
1Y Performance:
-61.08%
1-Day Range:
$0.7784
$0.90
1-Week Range:
$0.701
$0.91
52-Week Range:
$0.701
$2.93
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.7784 | 179.41M | 1.57M | -39.34M | -106.40M | -0.2388 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte Q4 2025 earnings preview - MSN
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development - Bitget
Humacyte appoints Rick McElheny as SVP of business development By Investing.com - Investing.com India
Dealmaker behind $660M sale joins Humacyte to build partnerships - Stock Titan
Aug Volume: Should I invest in Humacyte Inc Equity Warrant before earningsTrade Exit Report & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Investment Report: Can Humacyte Inc sustain its profitability2026 Market Overview & Community Trade Idea Sharing - baoquankhu1.vn
Targets Report: Can Humacyte Inc sustain its profitabilityIPO Watch & High Accuracy Buy Signal Tips - baoquankhu1.vn
HUMACYTE Q4 2025 Earnings Preview: Recent $HUMA Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Humacyte Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Humacyte secures $1.48M Symvess purchase commitment in Saudi Arabia - MSN
Income Plays: What are the analyst revisions for Air T IncIs Humacyte Inc stock a good investment in YEARMarket Activity Recap & Short-Term Swing Trade Alerts - baoquankhu1.vn
Humacyte secures minimum 1.475 million dollar Symvess vessel purchase for Saudi clinical rollout - Traders Union
Fresenius Medical Care (HUMA) updates 8.4% beneficial stake in Humacyte - Stock Titan
Is Humacyte (HUMA) Using Middle East Partnerships To Reframe Its Capital and Market Access Strategy? - Yahoo Finance
Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It? - Yahoo Finance
Humacyte Secures $1.5M Saudi Order – Why Did HUMA Stock Crash To Record Low Today? - Stocktwits
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026 - The Manila Times
HUMA (Humacyte, NASDAQ) pre-market 23 Mar 2026: earnings on Mar 27 could reset HUMA stock - Meyka
Humacyte secures $1.5M Saudi order – why did HUMA stock crash to record low today? - MSN
If You Invested $1,000 in Humacyte Inc (HUMA) - Stock Titan
Is Humacyte (HUMA) Using Middle East Traction And Equity Issuance To Redefine Its Risk Profile? - simplywall.st
Humacyte seeks Israeli approval for Symvess acellular vessel as breakthrough repair option - Traders Union
Profit Recap: Should I average down on Humacyte Inc stock2026 Trade Ideas & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Humacyte, Inc. (HUMA) Submits Marketing Authorization Application in Israel for Symvess - Insider Monkey
Humacyte Announces $20 Million Direct Offering to Fund Symvess Commercialization and Phase 3 Hemodialysis Milestone - Minichart
Humacyte raises $20 million in registered direct offering By Investing.com - Investing.com India
Humacyte (HUMA) Projected to Post Quarterly Earnings on Friday - MarketBeat
Humacyte secures $1.5M Saudi Arabia purchase commitment By Investing.com - Investing.com India
Analyst Calls: What is the long term forecast for Humacyte Inc stockDay Trade & Verified High Yield Trade Plans - baoquankhu1.vn
Humacyte Announces $20 Million Registered Direct Offering - TipRanks
Humacyte (NASDAQ: HUMA) to raise $20M selling 25M shares at $0.80 - Stock Titan
Humacyte (Nasdaq: HUMA) prices $20M registered direct stock sale - Stock Titan
Humacyte stock price target maintained at $6 by BTIG on Saudi deal - Investing.com Australia
HUMA Drops 19.6%: Sharp Downturn Triggered by $20M Sale Amid Market Turbulence - Bitget
Humacyte Receives Purchase Commitment For Symvess Product In Saudi Arabia - marketscreener.com
Humacyte raises $20 million in registered direct offering - Investing.com
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia - The Manila Times
Humacyte Ends ATM Program, Highlights Symvess Global Expansion - TipRanks
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock - The Manila Times
Saudi hospitals to evaluate Humacyte vessel under $1.475M deal - Stock Titan
Humacyte raises $20M to back Symvess launch and Phase 3 readout - Stock Titan
Humacyte (HUMA) halts $60M ATM as Symvess gains early sales and KSA deal - Stock Titan
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - MSN
Humacyte submits marketing application for Symvess in Israel By Investing.com - Investing.com South Africa
Risk Hedge: What is the long term forecast for Humacyte Inc stockWeekly Investment Report & Scalable Portfolio Growth Methods - baoquankhu1.vn
Humacyte stock rating reiterated at Buy by D. Boral Capital - Investing.com South Africa
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):